Альмитрин при хронической обструктивной болезни легких

1. Agusti A.G.N., Barbera J.A., Roca J. et al. Hypoxic pulmonary vasconstriction and gas exchange during exercise in chronic obstructive pulmonary disease. Chest 1990; 97: 268-275.

2. Almaraz L., Rigual R., Obeso A. et al. Effects of almitrine on the release of cate cholamines from the rabbit carotid body in vitro. Br. J. Pharmacol. 1992; 106: 697-702.

3. Alani S.М., Twomey J.A., Peake M.D. Almitrine and peripheral neuropathy. Lancet 1985; 2: 1251.

4. Ansquer J.C., Bertrand A., Blaive B. et al. Intérêt therapetique et acceptabilité du Vectarion 50 mg comprimes enrobes (bismesilate d'almitrine) a la dose de 100 mg /jour. Etude des résultats gazometriques, cliniques et biologiques en traitement prolonge pendant 1 an. Rev. Mal. Respir. 1985; 2 (suppl.l): S61-S65.

5. Arnaud F., Bertrand A., Charpin J. et al. Lebismesilate d'almitrine dans le traitement au long cours (sixmois) de l'insuffisance respiratoire chronique. Etude multicentrique a double insu. Bull Eur. Physiopathol. Respir. 1982; 18 (supp l.4): 372-382.

6. Avdeev S.N., Aisanov Z.R., Chuchalin A.G. Compliance as a critical issue in long-term oxygen therapy. Monaldi Arch. Chest Dis. 1999; 54: 61-66.

7. Bakran I., Vrhovac B., Stangl B. et al. Double-blind placebo controlled clinical trial of a lmitrine bismesylate in patients with chronic respiratory in sufficiency. Eur. J. Clin . Pharmacol. 1990; 38: 249-253.

8. Bardsley P.A., Howard P., DeBacker W. et al. Two years treatment with almitrine bismesylate in patients with hypoxic chronic obstructive airways disease. Eur. Respir. J. 1991; 4: 308-310.

9. Bardsley P.A., Howard P., Tang O. et al. Sequential treatment with low dose almitrine bismesylate in hypoxaemic chronic obstructive airways disease. Ibid. 1992; 5: 1054-1061.

10. Bell R.C., Mullins R.C., West L.G. et al. The effect of almitrine bism esylate on hypoxemia in chronic obstructive pulmonary disease. Ann. Intern. Med. 1986; 105: 342-346.

11. Block A.J., Boyson P.G., Wynne J.W. The origin of cor pulmonale, a hypotesis. Chest 1979; 75: 109.

12. Bromet N., Singlas E. Pharmacocinetique clinique du bismesilate d'almitrine. Presse Med. 1984; 13: 2071-2077.

13. Bury T., Jeannot J.P., Ansquer J.C., Radermecker M. Doseresponse and pharmacokinetic study with almitrine bismesylate after single oral administrations in COPD patients. Eur. Respir. J. 1989; 2: 49-55.

14. Castaing Y., Manier G., Varene N., Guenard H. Almitrine orale et distribution desrapports VA/Q dans les bronchopneumopathies chroniques obstructives. Bull. Eur. Physiopathol. Respir. 1981; 17: 917-932.

15. Castaing Y., Manier G., Guenard H. Improvement in ventilation-perfusion relations by almitrine in patients with chronic obstructive pulmonary disease during mechanical ventilation. Am. Rev. Respir. Dis. 1986; 134: 910-916.

16. Chedru F., Nodzenski R., Dunand J.F. Peripheral neuropathy during treatment with almitrine. Br. Med. J. 1985; 290: 896.

17. Chen L., Miller F.L., Malmkvist G. et al. High-dose almitrine bismesylate inhibits hypoxic pulmonary vasoconstriction in closed-chest dogs. Anesthesiology 1987; 67: 534-542.

18. Chen L., Miller F.L., Clarke W.R. et al. Low-dose almitrine bismesylate enhances hypoxic pulmonary vasoconstriction in closed chest dogs. Anesth. Analg. 1990; 71: 475-483.

19. Chuchalin A.G., Avdeev S.N. Epidemiology and management of COPD in Russia. In: Similowski T., Whitelaw W.A., Derenne J.-P., eds. Clinical management of stable COPD. New York: Marcel Dekker, Inc.; 2002. 987-1006.

20. Clark M.J., Bader G., Ansquer J.C. Le bismesilate d'almitrine diminue le nombre des infections bronchiques et des hospitalisations chez les patients atteints de bronchopneumopathie chronique obstructive. Un témoin du contrôle de l'evolutivite de la maladie sur plus de 1000 malades. Sem. Hop. 1988; 64: 2363-2368.

21. .Connaughton J.J., Douglas N.J., Morgan A.D. Almitrine improves oxygenation when both awake and asleep in patients with hypoxia and carbon dioxide retention caused by chronic bronchitis and emphysema. Am. Rev. Respir. Dis. 1985; 132: 206-210.

22. Cooper C.B., Waterhouse J., Howard P. Twelve year clinical study of patients with hypoxic cor pulmonale given long term domiciliary oxygen therapy. Thorax 1987; 42: 105-110.

23. De Backer W., Vermeire P., Bogaert E. et al. Almitrine has no effect on gas exchange after bilateral carotid body resection in severe chronic airflow obstruction. Bull. Eur. Physiopathol. Respir. 1985; 21: 427-432.

24. Duranti R., Scano G., Ambrosino N. Is there a place for respiratory analeptics or related drugs in stable CO PD patients? In: Similowski T., Whitelaw W .A., Derenne J.-P., eds. Clinical management of stable COPD. New York: Marcel Dekker, Inc.; 2002. 383-404.

25. Duroux P., Simonneau G., Lockhart A., Harj A. Modification des rapports ventilation-perfusion par le bismesilate d'almitrine chez le bronchitique chronique. Bull. Eur. Physiopathol. Respir. 1982; 18 (suppl.4): 337-338.

26. Escourrou P., Simonneau G., Ansquer J.C. et al. A single orally administered dose of almitrine improves pulmonary gas exchange during exercise in patients with chronic air-flow obstruction. Am. Rev. Respir. Dis. 1986; 133: 562-567.

27. Evans T.W., Tweney J., Waterhouse J.C. et al. Almitrine bismesylate and oxygen therapy in hypoxic cor pulmonale. Thorax 1990;45:16-21.

28. Fletcher E.C., Miller J., Divine G.W. et al. Nocturnal oxyhemoglobin desaturation in CO PD patients with arterial oxygen tensions about 60 mm Hg. Chest 1987; 92: 604-608.

29. Fletcher E.C., Luckett R.A., Goodnight-White S.A. et al. A double-blind trial of nocturnal supplemental oxygen for sleep desaturation in patients with chronic obstructive pulmonary disease and a daytime P a0 2 above 60 mm Hg. Am. Rev. Respir. Dis 1992; 145: 1070-1076.

30. Fletcher E.C. Nonconventional indications for LTOT: isolated nocturnal oxygen therapy in chronic lung disease. Monaldi Arch. Chest. Dis. 1999; 54: 67-71.

31. Gerard M ., Leger P., Couturier J.C., Robert D. Ten cases of peripheral neuropathy during treatment with almitrine in COPD patients. Eur. J. Respir. Dis. 1986; 69 (suppl. 146): 591-596.

32. Gherardi R., Benvenuti C., Lejonc Î.L. et al. Peripheral neuropathy in patients treated with almitrine bismesylate. Lancet 1985; 1: 1247-1250.

33. Global Initiative for Chronic Obstructive Lung Disease (G O LD ). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. N H L B I/ W H O Workshop Report. Publication Number 2701, April 2001. 1-100.

34. Gorecka D., Gorzelak K., Sliwinski P. et al. Effect of long-term oxygen therapy on survival in patients with chronic obstructive pulmonary disease with moderate hypoxaemia. Thorax 1997; 52: 674-679.

35. Gorecka D., Sliwinski P., Palasiew icz G. et al. Evolution comparative de la Pa02 chez des patients B PC O moderement hypoxemiques traites par almitrine versus placebo pendant un an. Rev. Mai. Respir. 2001; 18 (4, pt 2): S15-S17.

36. Gothe B., Cherniack N.S., Bachand R.T. et al. Long-term effects of almitrine bismesylate on oxygenation during wakefulness and sleep in chronic obstructive pulmonary disease. Am. J. Med. 1988; 84: 436-444.

37. Grassi V., Bottino G., Blasi A., Grassi C. La premiere experience Italienne avec bismesylate d'almitrine. Rev. Mai. Respir. 1985; 2 (suppl.1): S53-S60.

38. Jarratt J.A., Morgan C.N., Twomey J.A. et al. Neuropathy in chronic obstructive pulmonary disease: a multicentre electrophysiological and clinical study. Eur. Respir. J. 1992; 5-517-524.

39. Hawrylkiewicz I., Jedrzejewska-Makowska M., Gorecka D., Zielinski J. Effects of almitrine and oxygen on ventilation and gas exchange in patients with chronic respiratory insufficiency. Eur. J. Respir. Dis. 1983; 64: 512-516.

40. Howard P. Hypoxia, almitrine, and peripheral neuropathy. Thorax 1989; 44: 247-250.

41. Hurd S. The impact of COPD on lung health worldwide. Epidemiology and incidence. Chest 2000; 117: 1S-4S.

42. Lambropoulos S., Chatzipappas A., Tsekos G., Tsantoulis K. The role of almitrine bismesylate in acute respiratory failure. Eur. J. Respir. Dis. 1986; 69 (suppl.146): 657-661.

43. MacNee W., Zielinski J. Survival. Eur. Respir. Mon. 2000, 5 (13): 7-15.

44. Martno E. The pharmacological properties of almitrine bismesylate. Eur. J. Respir. Dis. 1986; 69: 619-632.

45. Marsac J. The assessment of almitrine bismesylate in the longterm treatment of chronic obstructive bronchitis. Ibid. 1986; suppl.146: 685-693.

46. Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; 1: 681-686.

47. Melot C., Naeije R., Rothschild T. et al. Improvement in ventilation-perfusion matching by almitrine in COPD. Chest 1983; 83: 528-533.

48. Nocturnal Oxygen Therapy Trial Group: Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann. Intern. Med. 1980; 93: 391-398.

49. O'Donohue W.J. Home oxygen therapy. Clin. Chest Med. 1997; 18: 535-545.

50. Payen D., Muret J., Beloucif S. et al. Inhaled nitric oxide, almitrine infusion, or their coadministration as a treatment of severe hypoxemic focal lung lesions. Anesthesiology 1998; 89: 1157-1164.

51. Prefaut C., Bourgouin-Karaoini D., Ramonatxo M. et al. A one year double blind follow-up of blood gas tensions and haemodynamics in almitrine bismesylate therapy. Eur. Respir. J. 1988; 1: 41-50.

52. Rigaud D., Dubois F., Godart J. et al. Effets de l'almitrine sur la ventilation et la perfusion régionales chez l'insuffisant respiratoire chronique. Rev. Fr. Mal. Respir. 1980; 8: 605-616.

53. Rigaud D., Dubois F., Godart J. et al. Modification des relations ventilation-perfusion dans les bronchopneumopathies chroniques obstructive après prise d'almitrine. Lyon Med. 1981: 245: 491-496.

54. Ringbaek T.J., Viskum K., Lange P. Does long-term oxygen therapy reduce hospitalisation in hypoxaemic chronic obstructive pulmonary disease? Eur. Respir. J. 2002; 20: 38-42.

55. Roch A., Papazian L., Bregeon F. et al. High or low doses of almitrine bismesylate in A RD S patients responding to inhaled NO and receiving norepinephrine? Intensive Care Med. 2001; 27: 1737-1743.

56. Rodman D.M., Voelkel, N.F. Regulation of vascular tone. In: Crystal R.G., West J.B., Weibel E.R., Barnes P.J., eds. The lung: scientific foundations. 2nd ed. Philadelphia: Lippincott-Raven; 1997. 1473-1492.

57. Romaldini H., Rodriguez-Roisin R., Wagner P., West J.B. Enhancement of hypoxic pulmonary vasoconstriction by almitrine in the dog. Am. Rev. Respir. Dis. 1983; 128: 288-293.

58. Saadjian A.Y., Philip-Joel F.F., Barret A. et al. Effect of almitrine bismesylate on pulmonary vasoreactivity to hypoxia in chronic obstructive pulmonary disease. Eur. Respir. J. 1994; 7: 862-868.

59. Stavchansky S., Dolusio J.T., Macleod C.M. et al. Single oral dose proportionality pharmacokinetics of almitrine bismesylate in humans. Biopharm. Drug. Dispos. 1989; 10: 229-237.

60. Stavchansky S., Dolusio S.T., Macleod C.M. et al. One year administration of almitrine bismesylate (Vectarion) to chronic obstructive pulmonary disease patients: pharmacokinetic analysis. Ibid. 247-255.

61. Stradling J.R., Nicholl C.G., Cover D. et al. Pattern of breathing and gas exchange following oral almitrine bismesylate in patients with chronic obstructive pulmonary disease. Eur. J. Respir. Dis. 1983; suppl. 126: 255-264.

62. Suggett A.J., Jarratt J.A., Proctor A., Howard P. Almitrine and peripheral neuropathy. Lancet 1985; 2: 830-831.

63. Tenaillon A., Labrousse S., Longchal J. et al. Effets de l'almitrine chez les insuffisants respiratoires chroniques en pousses asphyxiques traites par la ventilation atrtificielle. Bull. Eur. Physiopathol. Respir. 1980; 16: 203P-208P.

64. Tenaillon A., Salmona J.P., Coulaud J.M. et al. Les effets de l'almitrine par voie otrale dans les bronchopneumopathies chroniques obstructives traites par la ventilation atrtificielle. Lyon Med. 1981; 245(8): 487-490.

65. Voisin C., Wallaert B., Aerts C., Grosbois J.M. Action of almitrine dimesylate on the oxidant activities of alveolar macrophages. Rev. Med. Interne 1985; 6: 45-52.

66. Voisin C., Howard P., Ansquer J.C. Almitrine bismesylate: a long-term placebo-controlled double-blind study in COAD — Vectarion International Multicentre Study Group. Bull. Eur. Physiopathol. Respir. 1987; 23 (suppl.11): 169s— 182s.

67. Voisin C. The hypoxaemia in chronic obstructive pulmonary disease (CO PD ) and its management. Wiad. Lek. 1998; 51: 11-14.

68. Von Euler U.S., Liljestrand G. Observations on the pulmonary arterial blood pressure in the cat. Acta Physiol. Scand. 1946; 12: 301-320.

69. Wagner P.D., Dantzker D.R., Dueck R. et al. Ventilation-perfusion inequality in chronic obstructive pulmonary disease. J. Clin. Invest. 1977; 59: 203-216.

70. Wagner P.D., Rodriguez-Roisin R. Clinical advances in pulmonary gas exchange. Am. Rev. Respir. Dis. 1991; 143: 883-888.

71. Watanabe S., Kanner R.E., Cutillo A.G. et al. Long-term effect of almitrine bismesylate in patients with hypoxemic chronic obstructive pulmonary disease. Ibid. 1989; 140: 1269-1273.

72. Weitzenblum E., Schrijen F., Apprill M. et al. One year treatment with almitrine improves hypoxaemia but does not increase pulmonary artery pressure in COPD patients. Eur. Respir. J. 1991; 4: 1215-1222.

73. Weitzenblum E., Arnaud F., Bignon J. et al. Administration séquentielle d'une posologie réduite d'almitrine a des malades BPCO. Etude multicentrique contrôlée. Rev. Mal. Respir. 1992; 9: 455-463.

74. Winkelmann B.R., Leinberger H., Hertrich F.F. et al. Acute and chronic effects of low dose almitrine bismesylate in the treatment of chronic bronchitis and emphysema. Eur. J. Med. 1992; 1: 469-481.

75. Winkelmann B.R., Kullmer Т.Н., Kneissl D.G. et al. Low-dose almitrine bismesylate in the treatment of hypoxemia due to chronic obstructive pulmonary disease. Chest 1994; 105: 1383-1391.

76. Yamaguchi K., Mori М., Kawai A. et al. Inhomogeneties of ventilation and the diffusing capacity to perfusion in various chronic lung diseases. Am. J. Respir. Crit. Care Med. 1997; 156: 86-93.

77. Zielinski J., Sliwinski P., Tobiasz М., Gorecka D. Long-term oxygen therapy in Poland. Monaldi Arch. Chest Dis. 1993; 48 (5): 479-480.

78. Zielinski J., MacNee W., Wedzicha J. et al. Causes of death in patients with